CANCER DIAGNOSTICS MARKET The global cancer burden is significant with an estimated 50.6 million people living with cancer, 19.3 million new cases and 10.0 million deaths in 20201. The incidence of cancer is expected to rise to 28.4 million new cases by 2040 due to population aging and growth. Cancer is a leading cause of premature death with the highest burdens in China, Europe and North America. The cancer burden can be reduced by improved prevention, early detection, availability of cancer screening programs and effective treatment to improve patient outcomes and reduce mortality. Cancer is often detected at late-stage (stages III and IV) after symptoms have appeared, resulting in a poor prognosis for patients. Unfortunately, many existing diagnostic tests have high false-positives and/or insufficient sensitivity for early-stage cancer (stages I and II) and screening programs have poor participation rates due to the invasiveness, inconvenience, inaccessibility and cost of these tests. Earlier, more accurate and cost-effective diagnostics could improve treatment options, patient outcomes and survival for this expanding public health crisis2. INOVIQ is using its proprietary technologies to develop non-invasive blood tests to solve these problems for the screening, diagnosis, treatment selection and monitoring of cancer, including: – Screening tests for earlier detection of cancer – Predictive tests to guide therapeutic selection – Monitoring tests for treatment response and/or disease recurrence INOVIQ is targeting some of the world’s most common and deadliest cancers including breast and ovarian cancers. Breast cancer is the most common cancer with 2.3 million cases and 685 million deaths worldwide1, and a global diagnostics market valued at US$4.2 billion in 20213. Ovarian cancer is the world’s deadliest gynaecological cancer with 314,000 cases and 207,000 deaths worldwide1, and a global diagnostic market expected to reach over US$1.8 billion by 20264. EXOSOMES HAVE COMMERCIAL POTENTIAL FOR MULTIPLE DIAGNOSTIC AND THERAPEUTIC APPLICATIONS Exosomes are small extracellular vesicles (EVs) released by cells. They are nano-sized lipid membrane packages that encapsulate and protect DNA, RNAs and proteins. Exosomes and the messages they carry form part of the cell-to-cell communication system and play an important role in health and disease. Clinical interest in exosomes has grown exponentially due to their commercial potential in biomarker discovery, diagnosis and treatment of cancer, neurodegenerative, cardiology, immunology and other diseases. However, the exosome promise been limited by time-consuming and inefficient exosome isolation methods that are not suitable for commercial applications. This has created a need for improved exosome isolation methods that deliver speed, purity and yield for research and commercial applications. 1 Sung H et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021. https://doi.org/10.3322/caac.21660 2 SEER18 2010-2016 3 2 020. Breast Cancer Diagnostics Market, 2021-2028: https://www.grandviewresearch.com/industry-analysis/breast-cancerdiagnostics-market 4 2019. Ovarian Cancer Diagnostics Market. https://www.globenewswire.com/news-release/2019/08/07/1898453/0/en/OvarianCancer-Diagnostics-Market-Size-Worth-US-1-8-Bn-by-2026.htmlmarket-report/exosomes-market/189733/ 0 20 40 60 80 100 Late Average Early Bladder 6 6 3 10 39 28 21 59 49 93 30 30 90 99 100 77 96 98 Breast Lung Ovarian Pancreatic Prostate 5 year survival rates by stage at diagnosis (%) 9 Annual Report 2023
RkJQdWJsaXNoZXIy MjE2NDg3